Hangzhou Diagens Biotechnology Co., Ltd. engages in the development of medical imaging artificial intelligence (AI) technology. It operates through the following segments: iMedImage based Analysis Systems and Devices, Model Services, and Analaysis and Consulting Services. The iMedImage based Analysis Systems and Devices segment sells AI++ intelligent devices and systems. The Model Services segment offers Model-as-a-Service (MaaS) model services through its iMedImage medical imaging AI foundation model and MaaS technology platform, which provides tools to support self-training model customization. The Analysis and Consulting Services segment is involved in the provision of consulting services based on the analysis of the test results of chromosome karyotyping. The company was founded by Ning Song on September 19, 2016 and is headquartered in Hangzhou, China.